MicroRNAs in Pancreatic Cancer
MicroRNAs in Pancreatic Cancer
批准号:
7896664
负责人:
Ajay Pratap Singh
金额:
$7.42万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-20 至 2012-06-30
关键词:
Biochemical GeneticsBiological AssayBiological ProcessClinicalCytoplasmic ProteinDevelopmentERBB2 geneExtracellular MatrixGenesHumanLesionMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMembraneMicroRNAsMolecularMolecular ProfilingMucinsNeoplasm MetastasisOncogene ProteinsPancreasPancreatic AdenocarcinomaPancreatic carcinomaPhenotypePremalignantProteinsRegulationRegulator GenesRoleTherapeuticbasecancer celldesigninterestnoveloutcome forecastoverexpressionpancreatic neoplasmpublic health relevancetumor growthtumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Pancreatic cancer is a highly lethal malignancy with an extremely poor prognosis. A wide variety of biochemical and genetic aberrations have been identified to be associated with the pancreatic cancer. MUC4, encoding for a transmembrane mucin protein, is among the most differentially-expressed genes in pancreatic adenocarcinoma with no detectable expression in the normal pancreas. It is overexpressed in a significant number of pancreatic carcinomas, and its neoexpression is observed early in pancreatic tumor development i.e., in precancerous lesions. MUC4 has been shown to interact with and stabilize the expression of HER2 oncoprotein and contains structural motifs that can putatively interact with extracellular matrix, membrane and cytoplasmic proteins. MUC4 potentiates tumor growth and metastasis of pancreatic cancer cells and a recent study have shown that it is an independent factor for poor prognosis. All these studies underscore the importance of identifying the molecular mechanisms involved in the aberrant expression of MUC4, so that, it can be exploited clinically for therapeutic purposes. A new class of gene regulatory RNAs, termed as microRNAs (miRNAs) has gained significant interest for their ability to influence various biological process. A large number of miRNAs has been identified in humans. Nevertheless, the target mRNAs have been assigned to only a few of them. The hypothesis of this proposal is that the aberrant expression of a certain class of microRNAs in pancreatic cancer is responsible for MUC4 dysregulation and is implicated in the malignant progression of pancreatic cancer cells. This proposal will initiate efforts in three specific aims on investigating the expression profile of candidate MUC4-targeted miRNAs in pancreatic cancer (Aim 1), studying their role in MUC4 regulation (Aim 2), and characterize their effect on pancreatic cancer phenotype (Aim 3). Taken together, the proposed studies will unfold a novel regulatory mechanism for MUC4 expression in pancreatic cancer cells and ascribe the functional significance to the MUC4-targeted miRNAs in pancreatic cancer progression. The information gained from these studies will be vital in supporting the design of miRNA-based therapeutic strategies and clinical assays in pancreatic cancer. PUBLIC HEALTH RELEVANCE: The proposal will investigate the expression and functional significance of the candidate MUC4-targeted miRNAs in pancreatic cancer and may provide important information to support the design of miRNA-based therapeutic strategies and clinical assays for pancreatic cancer.
期刊论文(14)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.18632/oncotarget.2398
发表时间:
2014-09-30
期刊:
Oncotarget
影响因子:
--
作者:
[Tyagi N, Bhardwaj A, Singh AP, McClellan S, Carter JE, Singh S]
通讯作者:
Singh S
DOI:
10.1371/journal.pone.0021573
发表时间:
2011
期刊:
PloS one
影响因子:
3.7
作者:
[Arora S, Bhardwaj A, Srivastava SK, Singh S, McClellan S, Wang B, Singh AP]
通讯作者:
Singh AP
DOI:
10.1155/2015/848710
发表时间:
2015
期刊:
BioMed research international
影响因子:
--
作者:
[Srivastava SK, Arora S, Averett C, Singh S, Singh AP]
通讯作者:
Singh AP
DOI:
10.1016/j.canlet.2014.02.015
发表时间:
2014-06-01
期刊:
CANCER LETTERS
影响因子:
9.7
作者:
[Srivastava, Sanjeev K., Arora, Sumit, Singh, Seema, Bhardwaj, Arun, Averett, Courey, Singh, Ajay P.]
通讯作者:
Singh, Ajay P.
DOI:
10.2147/ijn.s61949
发表时间:
2014
期刊:
International journal of nanomedicine
影响因子:
8
作者:
[Arora S, Swaminathan SK, Kirtane A, Srivastava SK, Bhardwaj A, Singh S, Panyam J, Singh AP]
通讯作者:
Singh AP
共 12 条
A novel molecular cross-talk driving pancreatic cancer progression
-
批准号:10093980
-
项目类别:
-
资助金额:$34.66万
-
财政年份:2018
-
负责人:Ajay Pratap Singh
-
依托单位:
A novel molecular cross-talk driving pancreatic cancer progression
-
批准号:10335167
-
项目类别:
-
资助金额:$33.96万
-
财政年份:2018
-
负责人:Ajay Pratap Singh
-
依托单位:
Molecular determinant of racial disparity in prostate cancer
-
批准号:8847693
-
项目类别:
-
资助金额:$31.39万
-
财政年份:2014
-
负责人:Ajay Pratap Singh
-
依托单位:
Targeting tumor-stromal interaction for pancreatic cancer therapy
-
批准号:9199071
-
项目类别:
-
资助金额:$31.44万
-
财政年份:2014
-
负责人:Ajay Pratap Singh
-
依托单位:
Targeting tumor-stromal interaction for pancreatic cancer therapy
-
批准号:8631528
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2014
-
负责人:Ajay Pratap Singh
-
依托单位:
Targeting tumor-stromal interaction for pancreatic cancer therapy
-
批准号:8787996
-
项目类别:
-
资助金额:$31.36万
-
财政年份:2014
-
负责人:Ajay Pratap Singh
-
依托单位:
Targeting tumor-stromal interaction for pancreatic cancer therapy
-
批准号:9174192
-
项目类别:
-
资助金额:$7.88万
-
财政年份:2014
-
负责人:Ajay Pratap Singh
-
依托单位:
Molecular determinant of racial disparity in prostate cancer
-
批准号:8687364
-
项目类别:
-
资助金额:$31.33万
-
财政年份:2014
-
负责人:Ajay Pratap Singh
-
依托单位:
Molecular determinant of racial disparity in prostate cancer
-
批准号:9045588
-
项目类别:
-
资助金额:$31.44万
-
财政年份:2014
-
负责人:Ajay Pratap Singh
-
依托单位:
Myb, a key driver of pancreatic cancer progression and metastasis
-
批准号:8285965
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2012
-
负责人:Ajay Pratap Singh
-
依托单位:
Myb, a key driver of pancreatic cancer progression and metastasis
-
批准号:8450706
-
项目类别:
-
资助金额:$15.18万
-
财政年份:2012
-
负责人:Ajay Pratap Singh
-
依托单位:
MicroRNAs in Pancreatic Cancer
-
批准号:7740431
-
项目类别:
-
资助金额:$7.4万
-
财政年份:2009
-
负责人:Ajay Pratap Singh
-
依托单位:
海外基金